---
title: Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males
nct_id: NCT04391829
overall_status: UNKNOWN
phase: NA
sponsor: Universitair Ziekenhuis Brussel
study_type: INTERVENTIONAL
primary_condition: COVID-19
countries: Belgium
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04391829.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04391829"
ct_last_update_post_date: 2020-10-28
last_seen_at: "2026-05-12T06:24:30.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males

**NCT ID:** [NCT04391829](https://clinicaltrials.gov/study/NCT04391829)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 20
- **Lead Sponsor:** Universitair Ziekenhuis Brussel
- **Conditions:** COVID-19, Sars-CoV2, Corona Virus Infection, Semen
- **Start Date:** 2020-08-31
- **Completion Date:** 2021-08-31
- **CT.gov Last Update:** 2020-10-28

## Brief Summary

The objectives of the study, are to describe detection of SARS-CoV-2 in the semen of COVID-19 positive patients, the duration of positive semen and to investigate the impact on semen quality, thereby providing insights into the early impact on male reproductive function.

## Detailed Description

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), a novel coronavirus reported in late December 2019 in Wuhan, China, has spread world-wide with over 1,000,000 coronavirus disease 2019 (COVID-19) cases reported. New developments in molecular virology and immunobiology of SARS-CoV-2, improve our understanding about COVID-19 prevention, management, and possible long-term effects. Although viral transmission occurs predominantly through respiratory droplets, SARS-CoV-2 has been isolated in blood samples and feces from COVID-19 patients, raising questions about viral shedding in other bodily fluids, including semen, as well as alternative modes of transmission.

The objectives are to describe detection of SARS-CoV-2 in the semen of COVID-19 positive patients, the duration of positive semen and to investigate the impact on semen quality, thereby providing insights into the early impact on male reproductive function.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 50 Years
- **Sex:** MALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Male
* PCR on nasopharyngeal swab positive for SARS-CoV-2
* Age: ≥ 18y - ≤ 50y
* Signed informed consent
* When undergoing ART treatment: ICSI treatment

Exclusion Criteria:

* Negative test of SARS-CoV-2 on nasopharyngeal swab sample
* History of immunosuppression
* Impossibility to deliver a semen sample at UZ Brussel on a weekly base
* When undergoing ART treatment: IVF treatment
```

## Arms

- **SARS-CoV-2 positive men** (EXPERIMENTAL) — Men who are tested positive for SARS-CoV-2 by PCR testing on nasopharyngeal swab.

## Interventions

- **Ejaculated semen sample** (DIAGNOSTIC_TEST) — SARS-CoV-2 positive men will be asked to give an ejaculated semen sample, within the seven days after positive testing. Semen samples will be performed every 7 days, until 2 semen PCR tests are negative and will be retested after 3 months.

## Primary Outcomes

- **detection of SARS-CoV-2 in the semen** _(time frame: within 7 days after positive testing for SARS-CoV-2)_ — detection of SARS-CoV-2 in the semen of men positive for SARS-CoV-2 on nasopharyngeal swab

## Secondary Outcomes

- **duration of SARS-CoV-2 presence in semen** _(time frame: from first positive semen testing until first negative semen testing, upto 15 weeks)_
- **semen viscosity** _(time frame: from first until last semen analysis, upto 15 weeks)_
- **semen volume** _(time frame: from first until last semen analysis, upto 15 weeks)_
- **semen pH** _(time frame: from first until last semen analysis, upto 15 weeks)_
- **Sperm motility** _(time frame: from first until last semen analysis, upto 15 weeks)_
- **Sperm morphology** _(time frame: from first until last semen analysis, upto 15 weeks)_
- **Sperm density** _(time frame: from first until last semen analysis, upto 15 weeks)_

## Locations (1)

- UZ Brussel, Brussels, Belgium — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.uz brussel|brussels||belgium` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04391829.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04391829*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*